Evaluation of neratinib and everolimus in a panel of ER+ breast cancer in vitro and in vivo models of acquired AI resistance demonstrated that the combination of either agent with ET enhanced reductions in cell proliferation and tumor volume, and the greatest effect was observed with the triple combination of everolimus, neratinib, and ET53. The gene discussed is ESR1; the disease is breast carcinoma.